Privi Speciality Chemicals Limited has informed the Exchange about approval of scheme of Amalgamation/Merger by Board of Directors in their meeting held on June 14, 2025
PRIVISCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Privi Speciality Chemicals Limited (PSCL) announced that its Board has approved a scheme of amalgamation to merge Privi Fine Sciences Private Limited (PFSPL, a related party) and Privi Biotechnologies Private Limited (PBPL, its wholly owned subsidiary) into itself, under Sections 230-233 of the Companies Act, 2013. This supersedes the earlier June 24, 2024 plan to acquire PFSPL for cash — under the new structure, no cash will change hands. The share exchange ratio is fixed at 7.9897 equity shares of PSCL (face value ₹10) for every 7,000 equity shares of PFSPL (face value ₹10), while PBPL shares will be cancelled as it is a wholly owned subsidiary. The Board also decided NOT to proceed with the previously approved ₹1,000 crore Qualified Institutions Placement (QIP), citing improved performance and sufficient internal cash accruals. Post-merger, promoter holding will marginally rise from 74.05% to 74.67%, with public shareholding falling from 25.95% to 25.33%.
The merger is a value-accretive, non-cash consolidation that brings green science chemistry and biotech R&D capabilities into PSCL, while avoiding the cash outflow that the earlier acquisition plan would have required. The decision to skip the ₹1,000 crore QIP means no equity dilution for existing shareholders. However, the scheme still requires NCLT, SEBI, stock exchange, and shareholder approvals, and the slight increase in promoter shareholding may attract governance attention.